Cure8 research brief
This study identifies a plant-derived compound (poricoic acid A) that reduced inflammation, cellular senescence, and colon injury in cell and mouse models of ulcerative colitis and links those effects to AMPK/PPARγ signaling and shifts in the gut microbiome–metabolome.
That suggests new biological targets and a potential lead for future drug development relevant to IBD.
Researchers studying IBD mechanisms, drug discovery, microbiome–metabolome interactions, and clinicians interested in emerging preclinical therapeutics.
This preclinical study (cell and mouse models) tested poricoic acid A (PAA) in DSS-induced senescent intestinal epithelial cells and a DSS mouse model of ulcerative colitis.
The authors used multi-omics (transcriptomics, metagenomics, targeted metabolomics), network pharmacology, molecular docking, pharmacologic antagonists, and siRNA to show PAA activates PPARγ and downstream AMPK/Sirt1/PGC1α signaling, reduces cellular senescence and inflammation, and is associated with shifts in the gut microbiome–metabolome.
AMPK inhibition or PPARγ suppression reduced PAA’s protective effects in the models reported. PAA appears to be a lead compound with mechanistic data in vitro and in vivo but this is preclinical work; it does not provide clinical efficacy or safety data in people.
this is preclinical (cell culture and mouse) research reported in an academic journal abstract. Findings show biological plausibility and mechanism but do not demonstrate safety or effectiveness in humans; further studies including clinical trials would be required.
Review the original publication for the complete reporting, methods, and context.
This Cure8 brief is based on source text from the linked article. Cure8 is informational only and is not a substitute for professional medical advice, diagnosis, or treatment.
The study identifies a plant-derived compound that reduced inflammation and liver injury in a mouse model of ulcerative colitis and ties its effects to both JAK2/STAT1 inhibition and changes in the gut microbiota—two...
The study identifies a previously unrecognized protein (TNFAIP1) that appears to promote inflammation in ulcerative colitis and proposes a compound (Salidroside) that directly binds and inhibits it in lab and mouse...
Fibrosis and stricturing are key problems in Crohn’s disease with limited therapies; this study identifies a microbiota–bile acid–GPBAR1 pathway by which a specific probiotic mix reduced inflammation and fibrosis in...
